TAS-117 is under clinical development by Taiho Pharmaceutical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect TAS-117’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 22 Aug 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their TAS-117 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
TAS-117 is under development for the treatment of solid tumors including FGFR1 squamous cell lung cancer, ovarian clear cell carcinoma, endometrial cancer, breast cancer, colon cancer, ovarian cancer, cervical cancer, head and neck cancer, thyroid cancer, chondrosarcoma and g-PTEN aberrations cancer. It is a small molecule administered by orally. The drug candidate acts as selective non-ATP competitive inhibitor of AKT. It was under development for the treatment of gastric cancer and multiple myeloma.
Taiho Pharmaceutical overview
Taiho Pharmaceutical (Taiho), a subsidiary of Otsuka Group, develops and markets pharmaceutical products in the field of cancer, allergy, immunology and urology. Its product portfolio includes pharmaceutical products such as anti-allergic agents, anti-tumor agents, H2 receptor antagonists, antibiotics and medical devices; and consumer health products such as herbal digestive medicine, topical analgesics, antifungal cream and herbal medicine powder, among others. Taiho has production facilities in Tokushima, Saitama, Okayama, Kitajima and Inuyama. It operates through its subsidiaries situated worldwide including Japan, China, Canada, Singapore, the UK and the US. Taiho is headquartered in Tokyo, Japan.
Quick View TAS-117 LOA Data
|Highest Development Stage|